Literature DB >> 15509616

A novel murine model of cerebral scedosporiosis: lack of efficacy of amphotericin B.

Javier Capilla1, Emilio Mayayo, Carolina Serena, F Javier Pastor, Josep Guarro.   

Abstract

OBJECTIVES: Cerebral scedosporiosis is a life-threatening infection that is difficult to treat. The aim of this work was to develop a murine model of cerebral infection by Scedosporium apiospermum using intracranial inoculation and to use this model to evaluate the efficacy of amphotericin B deoxycholate and liposomal amphotericin B.
METHODS: Mice were rendered neutropenic by intraperitoneal cyclophosphamide and intravenous (iv) 5-fluorouracil administration. Animals were infected with iv or intracranial inoculation of 1 x 10(4), 5 x 10(4) or 5 x 10(5) cfu of a clinical strain of S. apiospermum. Tissue burden reduction was determined in kidneys and brain 4 days after the infection. Efficacy of amphotericin B and liposomal amphotericin B (0.8 mg/kg/day intraperitoneally and 40 mg/kg/day iv, respectively) was evaluated in neutropenic mice infected iv or intracranially with 5 x 10(4) cfu. Survival was analysed with the log-rank test. Fungal burden values of different groups were compared using the Mann-Whitney U-test.
RESULTS: In our model, intracranial infection produced a higher fungal load in the brain and a lower fungal load in the kidney than iv inoculation. Survival of animals infected intracranially and treated with amphotericin B or liposomal amphotericin B (mean survival time = 8.3 and 9.2 days, respectively) was not different from the control group (P=0.58 and 0.85, respectively).
CONCLUSIONS: We have developed a murine model of cerebral scedosporiosis, which may be useful for studying various pathological aspects of this infection and evaluating new therapeutic approaches. Amphotericin B and liposomal amphotericin B were unable to resolve the infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15509616     DOI: 10.1093/jac/dkh468

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  Experimental murine scedosporiosis: histopathology and azole treatment.

Authors:  M Mar Rodríguez; F Javier Pastor; Valentina Salas; Enrique Calvo; Emilio Mayayo; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

Review 2.  Infections caused by Scedosporium spp.

Authors:  Karoll J Cortez; Emmanuel Roilides; Flavio Quiroz-Telles; Joseph Meletiadis; Charalampos Antachopoulos; Tena Knudsen; Wendy Buchanan; Jeffrey Milanovich; Deanna A Sutton; Annette Fothergill; Michael G Rinaldi; Yvonne R Shea; Theoklis Zaoutis; Shyam Kottilil; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

3.  Identification of 14-α-Lanosterol Demethylase (CYP51) in Scedosporium Species.

Authors:  Anne Bernhardt; Wieland Meyer; Volker Rickerts; Toni Aebischer; Kathrin Tintelnot
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

4.  Susceptibility and diversity in the therapy-refractory genus scedosporium.

Authors:  M Lackner; F Hagen; J F Meis; A H G Gerrits van den Ende; D Vu; V Robert; J Fritz; T A A Moussa; G S de Hoog
Journal:  Antimicrob Agents Chemother       Date:  2014-07-28       Impact factor: 5.191

5.  Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis.

Authors:  Helen Box; Clara Negri; Joanne Livermore; Sarah Whalley; Adam Johnson; Laura McEntee; Ana Alastruey-Izquierdo; Jacques F Meis; Christopher Thornton; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

6.  In Vivo Efficacy of Olorofim against Systemic Scedosporiosis and Lomentosporiosis.

Authors:  S Seyedmousavi; Y C Chang; J H Youn; D Law; M Birch; J H Rex; K J Kwon-Chung
Journal:  Antimicrob Agents Chemother       Date:  2021-07-12       Impact factor: 5.191

Review 7.  Animal models: an important tool in mycology.

Authors:  Javier Capilla; Karl V Clemons; David A Stevens
Journal:  Med Mycol       Date:  2007-12       Impact factor: 4.076

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.